JNJ-4681

News alerts, weekly reports and conference planners

Company:

J&J

Drug class:

BTK inhibitor

Related drugs:

‹

›

CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	JNJ-6633 + JNJ-4681 Sensitive: D – Preclinical JNJ-6633 + JNJ-4681 Sensitive : D	JNJ-6633 + JNJ-4681 Sensitive: D – Preclinical JNJ-6633 + JNJ-4681 Sensitive : D
CD79B mutation	Diffuse Large B Cell Lymphoma	CD79B mutation	Diffuse Large B Cell Lymphoma	JNJ-4681 Sensitive: D – Preclinical JNJ-4681 Sensitive : D	JNJ-4681 Sensitive: D – Preclinical JNJ-4681 Sensitive : D

Associations
(2)